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A B S T R A C T
Spontaneous forms of the ovarian hyperstimulation syndrome (sOHSS) are nearly always reported between 8 and 14
weeks of pregnancy and also with follicle-stimulating hormone (FSH) producing pituitary adenoma. The syndrome has
been previously reported in rare instances of increased production of human chorionic gonadotrophin (hCG) such as
multiple pregnancies, hydatiforme mole, polycystic ovary disease and elevated concentrations of thyroid-stimulating
hormone (TSH) in hypothyreoidism. High levels of these hormones are able to stimulate by natural promiscuous activa-
tion the wild-type FSHr, resulting in sporadic presentations of the syndrome. Since 2003, only six different activating
FSHr gene mutations have been reported in cases of familial or habitual sOHSS. In addition to five mutations which
have been found in the transmembrane helices (Asp567Asn, Asp567Gly, Thr449Ile, Thr449Ala, Ile545Thr), the first
germline mutation (c.383C > A, p. Ser 128 Tyr) in the extracelullar domain was identified. All five mutants were abnor-
mally activated by TSH and normal levels of hCG while displaying constitutive activity. In contrast to these mutations,
the p.Ser128Tyr mutant displayed an increase in sensitivity only toward hCG. Accordingly, the mutated FSHrs, may be
hyperstimulated by the pregnancy-derived hCG or TSH, inducing the occurrence of the syndrome. In the differential di-
agnosis, malignancy, pregnancy luteoma and hyperreactio luteinalis would have to be excluded. In almost all of the cases
the disease regresses spontaneously and could be managed expectantly or conservatively, but with termination of preg-
nancy or surgery in cases of complications.
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Introduction
Ovarian hyperstimulation syndrome (OHSS) is a rare
and potentially life-threatening complication during con-
trolled ovarian stimulation. It can be associated with se-
vere morbidity and may even be fatal. Fortunately, the
prevalence of the severe form of OHSS is small, ranging
from 0.5–5%, or 0.2–1% as calculated by the World Health
Organization (WHO), of all stimulation cycles in assisted
reproduction. It is typically an iatrogenic complication of
ovulation induction associated with the use of exogenous
gonadotrophins and human chorionic gonadotrophin (hCG),
compounded by embryonic hCG in case of conception, oc-
curring during the luteal phase or early pregnancy. In its
most severe forms, OHSS involves massive ovarian en-
largement with multiple cysts, vascular hyperpermea-
bility, fluid shifts resulting in extravascular fluid accu-
mulation, hypovolemia, hemoconcentration, renal failu-
re, thromboembolic phenomena, and, even death1.
However, some extremely rare forms of sOHSS were
reported during pregnancy and may be associated with a
spontaneous ovulatory cycle. sOHSS have also been asso-
ciated with follicle-stimulation hormone (FSH) – pro-
ducing pituitary adenoma and it is thus not restricted to
pregnancies. The syndrome has been previously reported
in rare instances, most often in situations where there is
a supraphysiologic production of hCG, such as multiple
gestations or hydatiforme mole, polycystic ovary disease
and in cases of hypothyreoidism in pregnancy with the
high levels of thyroid-stimulating hormone (TSH)2. On
the other hand, there have been repeated reports of fa-
milial or habitual spontaneous cases of severe OHSS3–5.
Recently, several mutations of the FSH-receptor (FSHr)
were described in patients presenting with sOHSS of the
first trimester of pregnancy with normal levels of hCG4–6.
The absence or presence of FSHr mutations have allowed
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the creation of a pathophysiological classification of sOHSS
into three types. Type I corresponds to the mutated
FSHr cases, type II corresponds to the sOHSS secondary
to high levels of hCG and the third one is related to
hypothyreoidism6.
Pathophysiology
In the pathophysiology of OHSS, hCG, either exoge-
nous (to induce ovulation or as a luteal phase support) or
endogenous (pregnancy derived), is the factor which trig-
gers OHSS. Vascular endothelial growth factor (VEGF)
and VEGF-2 receptors are produced in human granu-
losa-lutein cells and VEGF acts
through its receptors as the main mediator because of
its prominent role in the pathologic vascular hyperper-
meability in response to hCG. In addition to, hCG and
VEGF individually produce a significant increase in VE-
-cadherin release, which is a soluble cell adhesion mole-
cule involved in the loosening of endothelial intercellular
junctions and may play a key role in the pathophysiology
and progression of vascular hyperpermeability7.
The pathophysiology of sOHSS has not been eluciated
yet. In certain circumstances – for example, in multiple
pregnancy or hydatid mole – it is theoretically possible
that there could be a greater likelihood of OHSS, since
hCG values may be raised above the normal level. How-
ever, even within these entities the prevalence of OHSS
is very low and only several cases have been observed8,9.
This could be taken as an indicator that hCG is a major,
but not the only, triggering mechanism in OHSS. More-
over, after excluding the cases with FSHr mutations, ges-
tational trophoblastic disease, multiple pregnancies and
iatrogenic OHSS, none of the patients with elevated hCG
experienced OHSS. It was suggested that elevated hCG
cannot be responsible for OHSS as a single factor and a
combination of mechanisms is responsible for this enig-
matic disorder10. Other cases of sOHSS were associated
with hypothyreoidism and it was suggested that the high
levels of TSH could stimulate the ovaries11,12. In addition
to, sOHSS in a woman with PCOS and in a singleton
pregnancy with otherwise normal history have been de-
scribed13,14. It has been shown in the cases of sOHSS
with no mutations in the FSHr gene, that high levels of
hCG or TSH were able to stimulate TSH and FSH recep-
tors in conditions that mimic high ligand concentrations.
High concentrations of hCG, as found in molar or multi-
ple pregnancies, and increased levels of TSH in hypothy-
reoidism, could therefore also stimulate the wild-type
FSH receptors expressed in developing follicles. This nat-
ural promiscuous activation of FSH receptors by high
levels of hCG and TSH is the likely explanation for these
sporadic sOHSS presentations6,15.
Since 2003, in several mutations of the FSHr of famil-
ial or habitual sOHSS, a molecular basis for the patho-
physiology of the sOHSS was identified and for the first
time –genetic evidence of a defect in the FSHr was found.
In addition to five different activating FSHr gene muta-
tions which have been found only in the transmembrane
helices (Asp567Asn, Asp567Gly, Thr449Ile, Thr449Ala,
Ile545Thr), the first germline mutation (c.383C > A, p.
Ser 128 Tyr) in the extracelullar domain of the FSHr re-
sponsible for sOHSS was identified. All five FSHr mu-
tants were abnormally sensitive and activated by TSH
and normal levels of hCG while displaying constitutive
activity. Contrary to these mutations, the p.Ser128Tyr
mutant displayed increase in affinity and sensitivity to-
ward hCG and did not show any constitutive activity, nor
promiscuous activity by TSH. The FSHr mutation ap-
pears to cause a reduction in ligand specifity, which
allowes activation of the mutated receptor by hCG. When
tested in vitro, the functional response of the mutant re-
ceptor displayed an enhanced basal activity and an in-
creased sensitivity to hCG. The abnormal functionality
of mutant FSH receptors in vitro provides a straight-
foward explanation for their implication in the OHSS de-
velopment in-vivo. The mutated FSHr expressed in the
developing follicles, abnormally sensitive to hCG, may be
hyperstimulated by the pregnancy-derived hCG. Accord-
ingly, the follicles may start growing, enlarge and finally
acquire luteinizing hormone receptors on granulosa cells
which may also be stimulated by hCG, inducing massive
follicular luteinization together with the secretion of
vasoactive mediators responsible for the development of
the syndrome. Moreover, TSH might also be capable of
stimulating a mutated FSHr in the same way as hCG
with hypothyreoidism4–6,16–18
In contrast, no mutations were found in the FSHr
from patients with high hCG or TSH levels, indicating
that for those patients, spontaneous OHSS results from
the natural promiscuous stimulation of a wild-type FSHr
by very high concentrations of hCG or TSH. However, in
all patients in whom no mutation was found in the FSHr
gene, the possibility that a somatic mutation with mani-
festations in the ovaries, but absent from leukocytes,
which could be responsible for the syndrome, cannot be
excluded. Such a mutation should occur very early in the
development to account for the bilateral involvement of
the ovaries, but in the absence of clinical indication for
ovarian biopsies, this hypothesis could not be tested as
suggested by Leener et al.6.
This molecular basis for the pathophysiology of spon-
taneous OHSS opens up new perspectives for a better
understanding of the way in which iatrogenic OHSS de-
velops. While a mutation in the FSHr gene should be
sought in patients with habitual or familial OHSS, it
would be interesting in iatrogenic cases of severe hyper-
stimulation to search for mutations in the hormone recep-
tor genes or glycoprotein hormone genes. It was found
that the FSHr genotype did not play a significant role be-
cause of the absence of FSHr activating mutations in
women with iatrogenic OHSS19. However, allelic variants
of FSH receptors have been associated with the response
to FSH in stimulation procedures, as well as with the se-
verity of OHSS when present20. Although a significant
enrichment in the allele N680 was observed as the sever-
ity of OHSS increased, identification of mutation of the
FSHr, Ser680Asn, in the FSHr gene cannot enable which
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patients will develop OHSS, but could predict the sever-
ity of symptoms among iatrogenic OHSS patients21.
Clinical Figure
Symptoms in cases of sOHSS appear later than those
in iatrogenic cases. Spontaneous forms of OHSS usually
develop between 8 and 14 weeks of pregnancy, differing
from iatrogenic OHSS generally starting between 3 and5
weeks amenorrhoea. In spontaneous cases, massive en-
largement of multiple follicles would be induced through
the hyperstimulation of the FSHr by endogenous hCG,
whereas in iatrogenic cases it would be induced endoge-
nous by FSH before ovulation. Both the constitutive ac-
tivity of the mutant receptor and its increased sensitivity
to hCG would be implicated in the generation of sOHSS.
Alternatively, the promiscuous activation of the FSHr by
hCG might be sufficient to induce the condition, as sug-
gested by the spontaneous occurrence of the syndrome in
patients with trophoblastic disease. As hCG usually peaks
between 8 and 10 weeks of pregnancy and declines there-
after, the initiation of follicular growth by pregnancy-de-
rived hCG could start between 6 and 10 weeks amenor-
rhoea. The occurrence of the symptoms is closely related
to the lifespan of the corpus luteum, and the develop-
ment the syndrome is expected to occur in parallel to the
massive follicular luteinization, thus between 8 and 14
weeks amenorrhoea culminating at the end of the first
trimester of pregnancy2,18.
Differential Diagnosis
Pregnancy luteoma, which is a nodular hyperplasia of
luteinized gonadal stromal or thecal cells, generally emer-
ges during the last trimester of pregnancy and regresses
spontaneously after delivery. Virilization is common in
these patients and in their female infants. This condition
is frequently unilateral and asymptomatic and the ma-
jority of cases are diagnosed unexpectedly by ultrasono-
grapy or during the course of cesarean section22. In con-
trast, hyperreactio luteinalis usually presents with bi-
lateral ovarian enlargement, which is caused by multiple
theca lutein cysts. It is generally asymptomatic and fre-
quently occurs in patients with gestational trophoblastic
disease, multiple pregnancies and fetal hydrops in the
third trimester of pregnancy23. In very rare cases of idio-
pathic sOHSS secondary to supraphysiologic secretion of
FSH, the presence of FSH-producing neuroendocrine tu-
mour and pituitary adenoma should be considered24,25.
To avoid unnecessary laparotomy, the importance of ca-
reful diagnosis with MR scans to differentiate spontane-
ous OHSS from ovarian cystic neoplasm should be em-
phasized26.
Diagnosis
In cases of normal Doppler ultrasonography and be-
nign ascitic cytology the possibility of malignancy could
be ruled out, and the diagnosis of sOHSS should be
considered27. The severity of the syndrome is related to
the degree of ovarian follicular response and estrogens
produced by the developing follicles, which may reach
high levels. Therefore, an estradiol level could serve as a
key marker of the degree of sOHSS28.
Treatment
Clinicians must bear the differential diagnosis of
sOHSS in mind if a patient presents with gross ascites
and other symptoms of ovarian cancer, which also may be
sign of OHSS. By taking all possible differential diagno-
ses into account, unnecessary laparotomy could be avoi-
ded 2. Since the syndrome is usually self-limiting, many
authors recommend the continuation of pregnancy. In
the almost all cases the disease regresses spontaneously
with the time or delivery. Although hospitalization is re-
quired in most cases the patient could be managed expec-
tantly without complications27. Conservative manage-
ment with thyroid hormone replacement seems to be the
best therapeutic approach for sOHSS women with un-
controlled hypothyroidism11. Monitoring of hemodyna-
mic status, intravenous crystalloid and albumin infusion,
prophylaxis of thrombosis and paracentesis are the main
principles of management28. Termination of pregnancy
can be considered when conservative management fails,
but surgery should be reserved only for cases of ovarian
rupture, torsion and intraperitoneal hemorrhage2,27.
Conclusion
Although sOHSS is a very rare complication of early
pregnancy between 8 and 14 wweks of amenorrhea, it
does not preclude a successful pregnancy outcome. The
importance of differential diagnosis is advisable in order
to prevent an unnecessary radical approach and to en-
able close observation with appropriate expectative and
conservative management of the syndrome.
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SPONTANI OVARIJSKI HIPERSTIMULACIJSKI SINDROM
S A @ E T A K
Spontani (s) oblici ovarijskog hiperstimulacijskog sindroma (OHSS) se javljaju skoro uvijek u trudno}i izme|u 8. i
14. tjedna, no isto tako i kod adenoma adenohipofize nastalim nastalim s folikularno stimuliraju}im hormonom (FSH).
Ranije se sindrom javljao u rijetkim slu~ajevima pove}anog stvaranja humanog korionskog gonadotropina (hCG) kao
{to su vi{estruke trudno}e, grozdasta mola, policisti~nih jajnika i povi{enih koncentracija tiroidnog stimuliraju}eg hor-
mona (TSH) u hipotireozi. Povi{ene razine ovih hormona bi prirodnom mije{anom aktivacijom poticale izvorni tip
receptora (r) FSH, {to bi rezultiralo sporadi~nom slikom sindroma. Od 2003. g. objavljeno je samo 6 razli~itih aktivi-
raju}ih mutacija FSHr u slu~ajevima familijarnog ili habitualnog sOHSS. Pored 5 mutacija receptora koje su na|ene u
membrani heliksa (Asp567Asn, Asp567Gly, Thr449Ile, Thr449Ala, Ile545Thr), identificirana je i prva mutacija na iz-
vanstani~noj domeni (c.383C > A, p. Ser 128 Tyr). Svih 5 mutacija nepravilno se aktiviraju s TSH i normalnim razina-
ma hCG, uz zadr`avanje konstitucijske aktivnosti. Nasuprot ovim mutacijama, p.Ser128Tyr mutacija odra`ava pove}a-
nu osjetljivost samo prema hCG. Tako promijenjeni FSHr mogu biti stimulirani od strane hCG izvedenog iz iz trudno}e
ili TSH, dovode do pojave sindroma. U diferencijalnoj dijagnozi treba isklju~iti zlo}udnu bolest, luteom trudno}e te
lutealnu hipereakciju. U gotovo svim slu~ajevima bolest nestaje spontano, a lije~i se ekspektativno ili konzervativno,
dok u slu~aju komplikacija kirur{ki ili prekidom trudno}e.
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